Israel has become the latest country to disclose plans to create a population-scale database of linked genetic and clinical records. The current plan is reminiscent of the United Kingdom's 100,000 Genomes Project, with Israel considering working with tech firms to create a database of patients with rare genetic diseases.
Sorrento Therapeutics, a frequent partner of billionaire biotech entrepreneur Patrick Soon-Shiong, launched a new subsidiary to advance its take on CAR-T therapies for cancer, taking a page from its patron as it tosses more and more irons in the R&D fire.
Medtronic is touting positive study results for its antibacterial envelope in high-risk patients who undergo cardiac device implantation, a feather in the company's cap as it continues to forge ahead with the innovative technology.
St. Jude Medical said in a new study that its CardioMEMS HF System can deliver improved outcomes and be cost-effective for heart failure patients who are already well-managed for their condition when they use pulmonary artery pressure monitoring.
The commercial potential of NASH, a common liver disease with no approved treatments, has seemingly launched a thousand R&D ships around the industry. And Novo Nordisk, emboldened by an investigator-sponsored study, might be sitting on an effective therapy for the pervasive ailment with liraglutide, a blockbuster already approved for diabetes and obesity.
Celgene's expansive approach to partnering continues to bear fruit, as two of the Big Biotech's in-licensed treatments have been added to the FDA's fast-track program, promising a speedy regulatory review as each approaches Phase III.
Some of the leaders in the field will be gathering for a special FierceBiotech panel discussion on clinical trial design and execution for cancer drugs at the upcoming annual meeting of BIO in Philadelphia on June 16.
Eleven Biotherapeutics' top pipeline prospect bombed a late-stage study in dry eye disease, failing to beat out placebo and forcing the Third Rock Ventures-founded biotech to pivot its focus.
Regeneron Pharmaceuticals is lobbying for the exome sequencing database it is building with Geisinger Health System to become the linchpin of President Obama's Precision Medicine program.
The Allen Institute for Brain Science has released an online database of neuron cell types, building blocks it thinks will lead to the creation of computer models of healthy brains. Publication of the free database marks an important, early milestone for the research program triggered by a $300 million donation from Microsoft co-founder Paul Allen in 2012.